JP2021500049A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021500049A5 JP2021500049A5 JP2020523011A JP2020523011A JP2021500049A5 JP 2021500049 A5 JP2021500049 A5 JP 2021500049A5 JP 2020523011 A JP2020523011 A JP 2020523011A JP 2020523011 A JP2020523011 A JP 2020523011A JP 2021500049 A5 JP2021500049 A5 JP 2021500049A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- seq
- isolated nucleic
- vector
- set forth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023220260A JP2024045131A (ja) | 2017-10-23 | 2023-12-27 | 神経変性疾患の遺伝子治療 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762575795P | 2017-10-23 | 2017-10-23 | |
| US62/575,795 | 2017-10-23 | ||
| US201862742723P | 2018-10-08 | 2018-10-08 | |
| US62/742,723 | 2018-10-08 | ||
| PCT/US2018/057187 WO2019084068A1 (en) | 2017-10-23 | 2018-10-23 | GENE THERAPIES FOR NEURODEGENERATIVE DISEASE |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023220260A Division JP2024045131A (ja) | 2017-10-23 | 2023-12-27 | 神経変性疾患の遺伝子治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021500049A JP2021500049A (ja) | 2021-01-07 |
| JP2021500049A5 true JP2021500049A5 (cg-RX-API-DMAC7.html) | 2021-11-25 |
| JP7413256B2 JP7413256B2 (ja) | 2024-01-15 |
Family
ID=66247008
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020523011A Active JP7413256B2 (ja) | 2017-10-23 | 2018-10-23 | 神経変性疾患の遺伝子治療 |
| JP2023220260A Pending JP2024045131A (ja) | 2017-10-23 | 2023-12-27 | 神経変性疾患の遺伝子治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023220260A Pending JP2024045131A (ja) | 2017-10-23 | 2023-12-27 | 神経変性疾患の遺伝子治療 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210261981A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3701030A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7413256B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20200075865A (cg-RX-API-DMAC7.html) |
| CN (2) | CN113005123A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018354195A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112020008033A2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA3083582A1 (cg-RX-API-DMAC7.html) |
| IL (2) | IL274129A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2020004207A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019084068A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020004005A (es) | 2017-10-03 | 2020-10-05 | Prevail Therapeutics Inc | Terapias genicas para los trastornos lisosomales. |
| EP3692158A4 (en) | 2017-10-03 | 2021-08-04 | Prevail Therapeutics, Inc. | GENE THERAPIES FOR LYSOSOMAL DISEASES |
| CN111542549A (zh) | 2017-10-03 | 2020-08-14 | 普利维尔治疗公司 | 用于溶酶体障碍的基因疗法 |
| EP3762505A4 (en) * | 2018-03-09 | 2021-12-01 | Avrobio, Inc. | COMPOSITIONS AND METHODS OF TREATMENT FOR PARKINSON'S DISEASE |
| HRP20251506T1 (hr) | 2019-04-10 | 2026-01-02 | Prevail Therapeutics, Inc. | Genska terapija za lizosomske poremećaje |
| JP7664848B2 (ja) | 2019-04-10 | 2025-04-18 | プリベイル セラピューティクス,インコーポレーテッド | リソソーム障害のための遺伝子療法 |
| EP4048794A4 (en) * | 2019-10-22 | 2024-04-17 | Applied Genetic Technologies Corporation | Triple function adeno-associated virus (aav) vectors for the treatment of c9orf72 associated diseases |
| EP4100527A2 (en) * | 2020-02-07 | 2022-12-14 | Maze Therapeutics, Inc. | Compositions and methods for treating neurodegenerative diseases |
| US20240294906A1 (en) * | 2020-07-29 | 2024-09-05 | Alnylam Pharmaceuticals, Inc. | Atxn2 irna compositions and methods of use thereof for treating or preventing atxn2-associated neurodegenerative diseases |
| JP2023545830A (ja) | 2020-10-15 | 2023-10-31 | プリベイル セラピューティクス,インコーポレーテッド | 組換えアデノ随伴ウイルス組成物及びその生産方法 |
| WO2022081985A1 (en) | 2020-10-15 | 2022-04-21 | Prevail Therapeutics, Inc. | Assay for measuring potency of gene therapy drug product |
| TWI910261B (zh) | 2020-11-06 | 2026-01-01 | 日商住友製藥股份有限公司 | Rps25基因之表現及/或功能調節劑 |
| JP2024505081A (ja) | 2021-01-28 | 2024-02-02 | エイブレイン | 神経変性疾患を治療するための遺伝子療法 |
| JP2024508635A (ja) | 2021-01-28 | 2024-02-28 | エイブレイン | 神経変性疾患を治療するための遺伝子療法 |
| KR102707250B1 (ko) | 2021-10-28 | 2024-09-13 | 한국해양과학기술원 | 신규 화합물 및 이를 유효성분으로 포함하는 신경염증성 뇌질환 예방 또는 치료용 조성물 |
| TW202340467A (zh) * | 2022-01-10 | 2023-10-16 | 賓州大學委員會 | 有用於治療c9orf72介導之病症之組成物及方法 |
| JP2025516136A (ja) | 2022-04-19 | 2025-05-27 | シャンハイ ヴァイタルゲン バイオファーマ カンパニー リミテッド | 神経変性疾患の治療のための組み換えaavベクター |
| JPWO2024257847A1 (cg-RX-API-DMAC7.html) | 2023-06-16 | 2024-12-19 | ||
| JP7684628B1 (ja) | 2024-03-21 | 2025-05-28 | 日本製鉄株式会社 | 自動車リアモジュール |
| WO2026064802A1 (en) * | 2024-09-23 | 2026-03-26 | The General Hospital Corporation | Gene therapy platform to restore gabaergic inhibition and improve cognition |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6204059B1 (en) * | 1994-06-30 | 2001-03-20 | University Of Pittsburgh | AAV capsid vehicles for molecular transfer |
| US20040053876A1 (en) * | 2002-03-26 | 2004-03-18 | The Regents Of The University Of Michigan | siRNAs and uses therof |
| US7829694B2 (en) * | 2002-11-26 | 2010-11-09 | Medtronic, Inc. | Treatment of neurodegenerative disease through intracranial delivery of siRNA |
| WO2004069173A2 (en) * | 2003-01-31 | 2004-08-19 | The Trustees Of The University Of Pennsylvania | Methods for modulating an inflammatory response |
| CA2596588C (en) * | 2005-01-31 | 2017-06-27 | University Of Iowa Research Foundation | Nucleic acid silencing of huntington's disease gene |
| JP5559185B2 (ja) * | 2008-11-11 | 2014-07-23 | オックスフォード バイオメディカ(ユーケー)リミテッド | 方法 |
| US20110142789A1 (en) * | 2009-12-10 | 2011-06-16 | The Trustees Of The University Of Pennsylvania | Compositions and Methods for the Diagnosis and Treatment of Amyotrophic Lateral Sclerosis |
| JP6091435B2 (ja) * | 2011-02-22 | 2017-03-08 | カリフォルニア インスティチュート オブ テクノロジー | アデノ随伴ウイルス(aav)ベクターを用いたタンパク質の送達 |
| PT2841578T (pt) * | 2012-04-23 | 2017-08-10 | Biomarin Tech Bv | Resumo |
| HK1214521A1 (zh) * | 2012-11-05 | 2016-07-29 | Genzyme Corporation | 用於治療蛋白質病的組合物和方法 |
| US20140271550A1 (en) * | 2013-03-14 | 2014-09-18 | The Trustees Of The University Of Pennsylvania | Constructs and Methods for Delivering Molecules via Viral Vectors with Blunted Innate Immune Responses |
| MY192689A (en) * | 2013-10-11 | 2022-09-01 | Ionis Pharmaceuticals Inc | Compositions for modulating c9orf72 expression |
| JP6756700B2 (ja) * | 2014-03-18 | 2020-09-16 | ユニバーシティ オブ マサチューセッツ | 筋萎縮性側索硬化症を処置するためのrAAVベースの組成物および方法 |
| SI3119888T1 (sl) * | 2014-03-19 | 2021-11-30 | Ionis Pharmaceuticals, Inc. | Sestavki za moduliranje izražanja ataksina 2 |
| WO2015153760A2 (en) * | 2014-04-01 | 2015-10-08 | Sangamo Biosciences, Inc. | Methods and compositions for prevention or treatment of a nervous system disorder |
| WO2016024205A1 (en) * | 2014-08-15 | 2016-02-18 | Pfizer Inc. | Oligomers targeting hexanucleotide repeat expansion in human c9orf72 gene |
| CN114717264A (zh) * | 2014-11-14 | 2022-07-08 | 沃雅戈治疗公司 | 治疗肌萎缩性侧索硬化(als)的组合物和方法 |
| EP3285788B1 (en) * | 2015-04-23 | 2024-12-18 | University of Massachusetts | Modulation of aav vector transgene expression |
| CA2985235A1 (en) * | 2015-05-07 | 2016-11-10 | Shire Human Genetic Therapies, Inc. | Glucocerebrosidase gene therapy for parkinson's disease |
| CA3016314A1 (en) * | 2016-03-02 | 2017-09-08 | Julianne REIDERS | Therapy for frontotemporal dementia |
| MX381216B (es) * | 2016-09-30 | 2025-03-12 | Regeneron Pharma | Animales no humanos que tienen una expansion de repeticiones de hexanucleotidos en un locus c9orf72. |
| WO2020053258A1 (en) * | 2018-09-12 | 2020-03-19 | Uniqure Ip B.V. | Rnai induced c9orf72 suppression for the treatment of als/ftd |
-
2018
- 2018-10-23 AU AU2018354195A patent/AU2018354195A1/en not_active Abandoned
- 2018-10-23 CA CA3083582A patent/CA3083582A1/en active Pending
- 2018-10-23 CN CN202110196181.XA patent/CN113005123A/zh active Pending
- 2018-10-23 MX MX2020004207A patent/MX2020004207A/es unknown
- 2018-10-23 EP EP18870021.5A patent/EP3701030A4/en not_active Withdrawn
- 2018-10-23 BR BR112020008033-0A patent/BR112020008033A2/pt not_active Application Discontinuation
- 2018-10-23 JP JP2020523011A patent/JP7413256B2/ja active Active
- 2018-10-23 KR KR1020207014683A patent/KR20200075865A/ko active Pending
- 2018-10-23 CA CA3177979A patent/CA3177979A1/en active Pending
- 2018-10-23 CN CN201880081355.4A patent/CN111819281B/zh active Active
- 2018-10-23 US US16/758,077 patent/US20210261981A1/en not_active Abandoned
- 2018-10-23 WO PCT/US2018/057187 patent/WO2019084068A1/en not_active Ceased
-
2020
- 2020-04-22 IL IL274129A patent/IL274129A/en unknown
-
2021
- 2021-02-23 IL IL281057A patent/IL281057A/en unknown
-
2023
- 2023-12-27 JP JP2023220260A patent/JP2024045131A/ja active Pending